CMMB — Chemomab Therapeutics Share News
0.000.00%
Last trade - 00:00Chemomab Therapeutics Ltd expected to post a loss of 15 cents a share - Earnings Preview
Israel's Chemomab Q4 net loss narrows on lower R&D spend
Brief: Chemomab Therapeutics Announces Nebokitug Phase 2 Spring Trial Results
Brief: Chemomab Therapeutics Announces Third Quarter 2025 Financial Results And Provides Corporate Update
Brief: Chemomab Announces Multiple Presentations at AASLD The Liver Meeting 2025 Featuring Clinical Data from the Nebokitug Phase 2 Trial in Primary Sclerosing Cholangitis
Chemomab Therapeutics Ltd expected to post a loss of 1 cent a share - Earnings Preview
Brief: Chemomab Reports Positive Results In Nebokitug Phase 2 PSC Open Label Extension Trial Showing Continued Broad And Substantial Improvements In Key Liver Biomarkers
Chemomab Therapeutics Ltd reports results for the quarter ended December 31 - Earnings Summary
Chemomab Therapeutics Ltd expected to post a loss of 8 cents a share - Earnings Preview
Chemomab Therapeutics Ltd reports results for the quarter ended September 30 - Earnings Summary
Chemomab Therapeutics Ltd expected to post a loss of 1 cent a share - Earnings Preview
Brief: Carl Gordon Reports 9.99% Stake In Chemomab Therapeutics As Of Sept 12 Versus 16.0% As Reported In March 11 - SEC Filing
Brief: Chemomab Therapeutics Ltd Files For Resale Of Up To 8.1 Mln ADSs By The Selling Shareholders
Chemomab Therapeutics Ltd reports results for the quarter ended in June - Earnings Summary
Chemomab Therapeutics Ltd expected to post a loss of 1 cent a share - Earnings Preview
Chemomab Therapeutics Ltd expected to post a loss of 1 cent a share - Earnings Preview
Brief: Chemomab Therapeutics Announces Positive Phase 2 Trial Results
Brief: Chemomab Awarded New European Patent For CM-101 In Phase 2 Clinical Development For Primary Sclerosing Cholangitis
Brief: Chemomab Therapeutics Q4 EPS USD 0.013